Soft tissue cellular components

Soft tissue cellular components refer to the diverse group of cells and extracellular matrix elements that constitute the non-skeletal tissues of the body, including muscle, fat, fibrous tissue, blood vessels, and the peripheral nervous system (National Cancer Institute, 2023). These components provide essential structural support, connect various body structures, and facilitate movement and nutrient transport. While not a single molecular target, these cellular components are the site of various pathologies, most notably soft tissue sarcomas, which are a heterogeneous group of rare tumors arising from mesenchymal cells (StatPearls, 2024). Therapeutic interventions in this area do not target the "soft tissue" as a whole but rather specific molecular pathways within these cells, such as vascular endothelial growth factor receptors (VEGFR) or platelet-derived growth factor receptors (PDGFR), to inhibit tumor growth or manage inflammatory conditions (PubMed, 2022). Because this term describes a broad histological category rather than a specific protein or gene, it is generally considered an incorrect designation for a therapeutic target in a molecular pharmacology context (NIH, 2023). Common biomarkers used to identify these components in pathology include vimentin, desmin, and S100, which help differentiate between various mesenchymal lineages (NIH, 2023).

Other names

Soft tissueMesenchymal tissueConnective tissueNon-epithelial extraskeletal tissue

Drugs associated with soft tissue pathologies typically act by inhibiting receptor tyrosine kinases (e.g., VEGFR, PDGFR), inducing DNA damage, or disrupting microtubule dynamics within mesenchymal cells (StatPearls, 2024).